Clinical Trial Update: Study of a Booster Dose of Hib-MenC Conjugate Vaccine vs Infanrix Hexa When Given to 14 Month Old Subjects [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing a Hib-MenC conjugate booster vaccine against Infanrix Hexa in 14-month-old children. The study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Haemophilus Influenzae Type Infection
• Meningococcal Disease

Drugs mentioned

• Hib-MenC conjugate booster vaccine (Haemophilus influenzae type b conjugate vaccine Hib-MenC)
• Infanrix Hexa (DTPa-HBV-IPV/Hib)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Neisseria Meningitidis, Haemophilus Influenzae Type b | Phase 3 | Status: COMPLETED